XML 13 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Related Party
3 Months Ended
Mar. 31, 2012
Related Party

2. Related Party

 

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending March 31, 2012 and 2011, MD Anderson related party research and development expense was $11,700 and $50,000, respectively. MD Anderson related party research and development expense for the quarter ending March 31, 2012 consisted of clinical trial expense of $11,700. As of March 31, 2012, the Company had accrued expense of $52,700 for clinical trial expense for the related party and $64,538 in accrued license payments payable due to the related party for current and past patent expenses for the Company’s Technology License. See Notes 5 and 6. For the quarter ended March 31, 2011, the Company had $50,000 in R&D related party expense for the clinical trial and annual license maintenance fee.